Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2023-05-24 Board/Management Inform…
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Otrzymanie kandydatury na Członka Rady Nadzorczej Spółki - Content (PL)
Board/Management Information Classification · 98% confidence The document is a formal announcement from the Management Board ('Zarząd') of Mabion S.A. regarding a nomination for a member of the Supervisory Board ('Rada Nadzorcza') ahead of the Annual General Meeting ('Zwyczajne Walne Zgromadzenie'). It details the candidate's qualifications, professional background, and compliance statements. This content directly relates to the composition and governance of the company's board, which aligns perfectly with the 'Board/Management Information' category. It is not a full report (10-K, IR), a dividend notice (DIV), or a voting result (DVA), but specifically about a management/board candidate nomination.
2023-05-24 Polish
Mabion_Pozostale_Informacje_do_Raportu Kwartalnego_2023_Q1
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly report ('raport kwartalny') for Mabion S.A. for the first quarter of 2023. It contains detailed financial data (balance sheet, income statement, cash flow), management discussion, and corporate governance information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-23 Polish
Mabion_MSSF 2023_Q1
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report (Śródroczne skrócone sprawozdanie finansowe) for Mabion S.A. covering the 3-month period ending March 31, 2023. It contains detailed financial statements, including the statement of comprehensive income, statement of financial position, and statement of cash flows. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. Q1 2023
2023-05-23 Polish
Zawarcie aneksu do umowy na dostawę bioreaktorów do zakładu wytwórczego Spółki - Content (PL)
Regulatory Filings Classification · 98% confidence The document is written in Polish and discusses an amendment (Aneks) to a previous agreement regarding the purchase of bioreactors. It details changes in delivery schedule, contract value (from 2.3 million EUR to 1.8 million EUR), and links these changes to the company's new 2023-2027 strategy. This type of announcement, concerning significant contractual changes, financing implications, or strategic operational shifts, typically falls under Capital/Financing Update (CAP) or sometimes Regulatory Filings (RNS) if it's a mandatory disclosure not covered elsewhere. Since it directly relates to a change in capital expenditure/asset acquisition value and strategic implementation, 'CAP' is a strong candidate. However, given the context of mandatory disclosure of material agreements and their amendments, and the lack of specific financing terms like debt issuance or equity changes, it is best classified as a general material event disclosure. In the provided definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' While this is an asset purchase amendment, it is a material transaction. If a more specific category like 'Material Event Disclosure' existed, it would fit there. Given the options, and that it is a report of a significant business transaction impacting future operations and value, it aligns closely with material corporate actions. Since it is not a standard financial report (10-K, IR, ER), and not explicitly about M&A, I will classify it as a general material disclosure, which defaults to RNS, or potentially CAP if the change in contract value is deemed a financing/capital event. Given the nature of reporting material changes to contracts that affect future operations and value, and lacking a specific 'Material Transaction' code, RNS (Regulatory Filings) is the safest fallback for significant, non-standard disclosures. However, since it involves a change in the value of a major commitment, I will lean towards CAP as it impacts the company's financial commitments/structure, though RNS is also plausible. I will select RNS as the most appropriate general regulatory disclosure for material, non-standard business updates not covered by other specific financial/governance codes.
2023-05-22 Polish
Wypowiedzenie przez Spółkę umowy z Parexel na przeprowadzenie badania klinicznego MabionCD20 - Content (PL)
Regulatory Filings Classification · 95% confidence The document text discusses a decision by the Management Board ('Zarząd Mabion S.A.') to terminate an agreement ('Umowa') related to a clinical trial (MabionCD20). This decision is explicitly linked to the company's strategy ('Strategii Spółki Mabion S.A. na lata 2023-2027'). The content focuses on strategic direction, operational changes, and future plans regarding drug development and CDMO transformation. This aligns best with Management Reports (MDA), which cover management's explanation of business trends and outlook, or potentially Regulatory Filings (RNS) if it were a general update. Given the detailed explanation of strategic alignment driving the operational decision, MDA is the most appropriate fit over the general RNS category. The document length (1338 chars) is short, but it contains substantive information about management decisions and strategy, not just an announcement of another report, thus avoiding the RPA classification.
2023-05-22 Polish
Raport niezależnego biegłego rewidenta z usługi atestacyjnej dotyczącej oceny Sprawozdania o wynagrodzeniach
Audit Report / Information Classification · 98% confidence The document is titled "Raport niezależnego biegłego rewidenta z usługi atestacyjnej dotyczącej oceny Sprawozdania o wynagrodzeniach" (Independent auditor's report on the assurance service regarding the assessment of the Remuneration Report). It explicitly discusses the verification of a 'Sprawozdanie o wynagrodzeniach' (Remuneration Report) against Polish public offering law requirements (art. 90g of the Act on Public Offering). The content is a formal audit/assurance report provided by an independent auditor (PwC) concerning the completeness and compliance of a specific management disclosure document. This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, especially since the subject matter is compensation disclosure, which is often covered under specific governance/remuneration reporting requirements that necessitate external assurance. FY 2022
2023-05-11 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.